TESTING (Confidence: 87)
LONGNAME, (Confidence: 59)
MARYLOUWCH (Confidence: 65)
SEX:F (Confidence: 28)
DOB: (Confidence: 93)
a (Confidence: 58)
NOV (Confidence: 95)
1981 (Confidence: 94)
‘ (Confidence: 60)
Sinai (Confidence: 80)
| (Confidence: 80)
Mount (Confidence: 96)
Sinai (Confidence: 84)
Hospital (Confidence: 96)
Pathology (Confidence: 90)
. (Confidence: 73)
12 (Confidence: 86)
COLLeae (Confidence: 21)
f (Confidence: 0)
ef (Confidence: 51)
Health (Confidence: 93)
| (Confidence: 91)
Jones (Confidence: 13)
von (Confidence: 13)
sed (Confidence: 42)
pea (Confidence: 20)
so (Confidence: 38)
Urive-ety (Confidence: 0)
hw (Confidence: 52)
TORONTO (Confidence: 71)
ON (Confidence: 90)
MOM (Confidence: 45)
2PY (Confidence: 0)
T; (Confidence: 63)
16888-1171 (Confidence: 3)
C (Confidence: 45)
616-546-4800 (Confidence: 55)
x4. (Confidence: 64)
eee (Confidence: 16)
= (Confidence: 27)
mic (Confidence: 19)
ennee (Confidence: 0)
nae (Confidence: 7)
icant (Confidence: 0)
Rue (Confidence: 3)
PRO: (Confidence: 9)
PATENT, (Confidence: 25)
ATTENDING (Confidence: 70)
PHYSICIAN (Confidence: 32)
CSU:66418 (Confidence: 9)
Physician: (Confidence: 0)
BOLLEGALA, (Confidence: 90)
DR. (Confidence: 92)
NATASHA (Confidence: 93)
First, (Confidence: 20)
Mocedie: (Confidence: 22)
warvcouwen (Confidence: 25)
MLN (Confidence: 28)
MU (Confidence: 56)
eres (Confidence: 15)
Looe (Confidence: 15)
Procedure (Confidence: 95)
Date: (Confidence: 60)
20) (Confidence: 20)
2d-D5-34 (Confidence: 20)
DOSiGender (Confidence: 0)
28 (Confidence: 93)
Saar (Confidence: 0)
1981 (Confidence: 90)
Accession (Confidence: 67)
Date: (Confidence: 89)
2024-05-31 (Confidence: 85)
Health (Confidence: 94)
Card (Confidence: 85)
#: (Confidence: 67)
Report (Confidence: 90)
Date: (Confidence: 61)
= (Confidence: 12)
2024-07-12" (Confidence: 68)
Viet# (Confidence: 29)
7218 (Confidence: 92)
202610 (Confidence: 79)
SUPPLEMENTAL (Confidence: 96)
SURGICAL (Confidence: 95)
PATHOLOGY (Confidence: 95)
REPORT (Confidence: 95)
a (Confidence: 0)
Copies (Confidence: 90)
to: (Confidence: 95)
ray (Confidence: 24)
SUPPLEMENTAL (Confidence: 95)
INFORMATION: (Confidence: 95)
S (Confidence: 0)
5 (Confidence: 0)
hS (Confidence: 0)
ADDENOUM (Confidence: 86)
(une (Confidence: 0)
6th, (Confidence: 64)
2024): (Confidence: 88)
~ (Confidence: 36)
@ (Confidence: 9)
x (Confidence: 29)
Immunohistochermstry’ (Confidence: 30)
“Ss (Confidence: 0)
Wa” (Confidence: 53)
Mismateh (Confidence: 89)
Repair (Confidence: 65)
(MMR): (Confidence: 89)
MLH1 (Confidence: 52)
deficient (Confidence: 83)
(abnormal (Confidence: 66)
MLH1 (Confidence: 77)
/ (Confidence: 47)
PMS2 (Confidence: 47)
staining (Confidence: 82)
dMMR) (Confidence: 77)
A. (Confidence: 67)
Tumour (Confidence: 96)
considered (Confidence: 84)
WSi-H (Confidence: 21)
ca (Confidence: 43)
PD-L1t: (Confidence: 26)
Positive (Confidence: 95)
(OPS (Confidence: 85)
> (Confidence: 85)
5 (Confidence: 94)
(40) (Confidence: 94)
HER2: (Confidence: 60)
Negative (Confidence: 69)
(03 (Confidence: 66)
ADDENDUM (Confidence: 95)
(July (Confidence: 94)
12 (Confidence: 91)
2024), (Confidence: 79)
“ (Confidence: 0)
Molecular (Confidence: 96)
Analysis (Confidence: 81)
MLH1 (Confidence: 15)
Promoter (Confidence: 90)
Metnyiation’ (Confidence: 34)
PRESENT (Confidence: 92)
IF (Confidence: 87)
COMMENT (Confidence: 96)
CAE (Confidence: 41)
Given (Confidence: 96)
the (Confidence: 96)
molecular (Confidence: 0)
findings, (Confidence: 96)
the (Confidence: 96)
loss (Confidence: 51)
of (Confidence: 93)
MLH1 (Confidence: 17)
is (Confidence: 86)
most (Confidence: 95)
likely (Confidence: 92)
sporadic (Confidence: 93)
in (Confidence: 93)
nature. (Confidence: 91)
Untess (Confidence: 84)
there (Confidence: 96)
is (Confidence: 96)
a (Confidence: 91)
sugge (Confidence: 90)
a (Confidence: 88)
hereditary (Confidence: 93)
Gandition (Confidence: 86)
(i.e. (Confidence: 48)
compelling (Confidence: 32)
family (Confidence: 93)
hestory, (Confidence: 81)
diagnosis (Confidence: 0)
under (Confidence: 95)
age (Confidence: 96)
50. (Confidence: 62)
polyposis), (Confidence: 95)
then (Confidence: 96)
a (Confidence: 68)
referral (Confidence: 91)
to (Confidence: 95)
genetics (Confidence: 96)
is (Confidence: 81)
not (Confidence: 94)
indicated (Confidence: 92)
at (Confidence: 94)
this (Confidence: 91)
tme, (Confidence: 84)
UL (Confidence: 61)
2 (Confidence: 75)
Molecular (Confidence: 84)
Testing (Confidence: 90)
— (Confidence: 81)
Technical (Confidence: 96)
Details (Confidence: 68)
3 (Confidence: 96)
2024 (Confidence: 89)
OMA (Confidence: 94)
extracted (Confidence: 95)
from (Confidence: 95)
microdissected (Confidence: 90)
tumour (Confidence: 96)
tissue (Confidence: 93)
was (Confidence: 94)
treated (Confidence: 95)
with (Confidence: 96)
sodium (Confidence: 62)
bsulfite, (Confidence: 65)
followed (Confidence: 95)
by (Confidence: 96)
amplification (Confidence: 76)
of (Confidence: 95)
a (Confidence: 95)
segment (Confidence: 76)
of (Confidence: 96)
the (Confidence: 91)
MLH1 (Confidence: 83)
[NM_000249.3] (Confidence: 17)
promoter (Confidence: 95)
region (Confidence: 91)
(0.-248_-178) (Confidence: 32)
using (Confidence: 96)
methylation (Confidence: 96)
specific (Confidence: 95)
real-time (Confidence: 51)
PCR (Confidence: 94)
on (Confidence: 72)
the (Confidence: 96)
Roche (Confidence: 84)
LightCyoler (Confidence: 40)
$6, (Confidence: 73)
The (Confidence: 85)
methylation (Confidence: 90)
status (Confidence: 96)
of (Confidence: 93)
MLH1 (Confidence: 81)
js. (Confidence: 74)
determined (Confidence: 96)
by (Confidence: 93)
calouileting (Confidence: 26)
the (Confidence: 96)
percentage (Confidence: 96)
of (Confidence: 96)
methylated (Confidence: 96)
feference (Confidence: 47)
(PMR) (Confidence: 63)
by (Confidence: 94)
comparing (Confidence: 82)
the (Confidence: 93)
ampiificaten (Confidence: 55)
of (Confidence: 92)
MLH1 (Confidence: 24)
to (Confidence: 80)
the (Confidence: 96)
amplification (Confidence: 20)
of (Confidence: 94)
the (Confidence: 94)
reference (Confidence: 96)
gene (Confidence: 95)
Alu, (Confidence: 95)
Methylation (Confidence: 33)
at (Confidence: 95)
locations (Confidence: 94)
other (Confidence: 94)
{han (Confidence: 56)
those (Confidence: 94)
covered (Confidence: 96)
by (Confidence: 96)
the (Confidence: 96)
primers (Confidence: 96)
and (Confidence: 96)
probes (Confidence: 95)
will (Confidence: 95)
not (Confidence: 96)
be (Confidence: 96)
detected, (Confidence: 96)
Results (Confidence: 42)
of (Confidence: 96)
this (Confidence: 96)
test (Confidence: 96)
must (Confidence: 96)
always (Confidence: 89)
be (Confidence: 95)
interpreted (Confidence: 91)
within (Confidence: 94)
the (Confidence: 94)
clinical (Confidence: 90)
context (Confidence: 95)
and (Confidence: 92)
other (Confidence: 79)
relevant (Confidence: 95)
data, (Confidence: 95)
and (Confidence: 93)
shauld (Confidence: 85)
not (Confidence: 96)
be (Confidence: 96)
used (Confidence: 96)
alone (Confidence: 96)
for (Confidence: 87)
2 (Confidence: 51)
diagnosis (Confidence: 57)
of (Confidence: 96)
malignancy (Confidence: 74)
This (Confidence: 96)
test (Confidence: 81)
is (Confidence: 81)
not (Confidence: 95)
intended (Confidence: 92)
to (Confidence: 96)
detect (Confidence: 96)
minimal (Confidence: 95)
residual (Confidence: 96)
decease (Confidence: 0)
These (Confidence: 96)
tests (Confidence: 84)
were (Confidence: 96)
developed (Confidence: 96)
and (Confidence: 96)
their (Confidence: 96)
performance (Confidence: 96)
characteristics (Confidence: 96)
determined (Confidence: 96)
by (Confidence: 96)
Mount (Confidence: 95)
Sinai (Confidence: 96)
Hospital, (Confidence: 85)
Department (Confidence: 91)
of (Confidence: 96)
Pathology (Confidence: 17)
and (Confidence: 87)
Laboratory (Confidence: 50)
Medicine. (Confidence: 85)
This (Confidence: 93)
laboiatery (Confidence: 48)
is (Confidence: 44)
accredited (Confidence: 84)
to (Confidence: 87)
|SO (Confidence: 40)
15189 (Confidence: 93)
Plus (Confidence: 96)
by (Confidence: 96)
Accreditation (Confidence: 88)
Canada (Confidence: 95)
Diagnostics. (Confidence: 71)
These (Confidence: 96)
tests (Confidence: 94)
were (Confidence: 96)
validated (Confidence: 89)
according (Confidence: 29)
to (Confidence: 96)
accepted (Confidence: 95)
practice (Confidence: 93)
quidelines (Confidence: 92)
for (Confidence: 97)
clinical (Confidence: 94)
molecular (Confidence: 95)
genetic (Confidence: 80)
testing (Confidence: 93)
by (Confidence: 96)
the (Confidence: 93)
ACMG (Confidence: 91)
anc (Confidence: 86)
CCMG. (Confidence: 75)
PATHOLOGY (Confidence: 96)
DIAGNOSIS. (Confidence: 73)
1,2. (Confidence: 43)
Duodenum (Confidence: 59)
(D2. (Confidence: 82)
cap), (Confidence: 86)
biopsies: (Confidence: 93)
~ (Confidence: 20)
Mild (Confidence: 94)
intraepithelial (Confidence: 19)
lymphocytosis (Confidence: 27)
(likely (Confidence: 91)
secondary (Confidence: 83)
to (Confidence: 96)
Helicobacter (Confidence: 93)
pylari (Confidence: 91)
gastritis) (Confidence: 95)
3, (Confidence: 87)
Stomach (Confidence: 95)
(antrum (Confidence: 84)
and (Confidence: 96)
body}, (Confidence: 90)
biopsy: (Confidence: 46)
- (Confidence: 53)
Active (Confidence: 96)
chronic (Confidence: 77)
gastritis; (Confidence: 94)
Helicobacter (Confidence: 91)
pylon (Confidence: 66)
identified (Confidence: 93)
with (Confidence: 95)
histochemical (Confidence: 43)
stains (Confidence: 92)
(H. (Confidence: 9)
pylon (Confidence: 55)
gastritis) (Confidence: 94)
« (Confidence: 79)
Intestinal (Confidence: 95)
metaplasia; (Confidence: 90)
negative (Confidence: 78)
for (Confidence: 96)
dysplasia (Confidence: 89)
4. (Confidence: 66)
Stomach (Confidence: 83)
(mass), (Confidence: 96)
biopsy (Confidence: 96)
+ (Confidence: 75)
Moderately (Confidence: 81)
differentiated (Confidence: 96)
gastric (Confidence: 88)
adenocarcinoma (Confidence: 94)
(intestinal (Confidence: 45)
type) (Confidence: 88)
- (Confidence: 55)
immune (Confidence: 52)
nistocherical (Confidence: 30)
beamarkers (Confidence: 68)
pending (Confidence: 94)
«Sinai (Confidence: 0)
| (Confidence: 65)
Mount (Confidence: 95)
Sinai (Confidence: 95)
Hospital (Confidence: 96)
Pathology (Confidence: 93)
& (Confidence: 93)
Laboratory (Confidence: 96)
Medicine (Confidence: 96)
Le (Confidence: 31)
Health (Confidence: 88)
| (Confidence: 68)
Jsseeh (Confidence: 0)
8 (Confidence: 49)
Wolt (Confidence: 13)
Leboric (Confidence: 19)
Heatth (Confidence: 19)
Compzex (Confidence: 12)
800 (Confidence: 83)
University (Confidence: 64)
Ave (Confidence: 84)
, (Confidence: 84)
Suite (Confidence: 71)
6500, (Confidence: 76)
Toronto, (Confidence: 86)
ON, (Confidence: 89)
Canada, (Confidence: 14)
WG (Confidence: 51)
155 (Confidence: 45)
t (Confidence: 79)
ATE (Confidence: 31)
586.4800 (Confidence: 31)
04457 (Confidence: 34)
f; (Confidence: 53)
416-506-8624 (Confidence: 54)
Chiruc (Confidence: 17)
td: (Confidence: 51)
ENDO (Confidence: 91)
Meckcal (Confidence: 47)
Record (Confidence: 38)
# (Confidence: 38)
BOGB2035 (Confidence: 0)
Clinic (Confidence: 85)
Name; (Confidence: 59)
= (Confidence: 73)
ENDOSCOPY (Confidence: 92)
Last (Confidence: 77)
Name (Confidence: 62)
 TESTINGLONGNAME, (Confidence: 48)
Physician: (Confidence: 24)
BOLLEGALA, (Confidence: 72)
DR, (Confidence: 95)
NATASHA (Confidence: 96)
First, (Confidence: 5)
Mickdie: (Confidence: 42)
MARYLOUWCH (Confidence: 90)
| (Confidence: 76)
Procedure (Confidence: 82)
Date: (Confidence: 67)
2024-05-31 (Confidence: 88)
DoRiGender (Confidence: 18)
28 (Confidence: 96)
NOV (Confidence: 95)
1981 (Confidence: 95)
Accession (Confidence: 56)
Date; (Confidence: 94)
2024-05-31 (Confidence: 92)
Health (Confidence: 92)
Car (Confidence: 7)
# (Confidence: 73)
Report (Confidence: 85)
Date! (Confidence: 71)
2024.07.12" (Confidence: 65)
a (Confidence: 11)
ae (Confidence: 31)
T21S (Confidence: 49)
20asIG (Confidence: 0)
SUPPLEMENTAL (Confidence: 96)
SURGICAL (Confidence: 95)
PATHOLOGY (Confidence: 96)
REPORT (Confidence: 96)
SPS-24-15414 (Confidence: 85)
COMMENT (Confidence: 95)
Biomarker (Confidence: 92)
results (Confidence: 92)
will (Confidence: 95)
be (Confidence: 96)
reported (Confidence: 96)
in (Confidence: 90)
a (Confidence: 90)
supplemental (Confidence: 95)
report (Confidence: 96)
Specimen: (Confidence: 71)
1. (Confidence: 85)
DUODENUM (Confidence: 69)
BIOPSY (Confidence: 86)
2 (Confidence: 96)
DUODENUM (Confidence: 93)
BIOPSY, (Confidence: 96)
CAP (Confidence: 96)
3. (Confidence: 87)
GASTRIC (Confidence: 87)
ANTRUM (Confidence: 94)
BIOPSY, (Confidence: 95)
AND (Confidence: 95)
BODY (Confidence: 93)
4 (Confidence: 96)
GASTRIC (Confidence: 95)
BIOPSY, (Confidence: 74)
MASS (Confidence: 94)
Gross (Confidence: 96)
Description (Confidence: 95)
1, (Confidence: 96)
The (Confidence: 95)
specimen (Confidence: 96)
container (Confidence: 95)
is (Confidence: 95)
labelled (Confidence: 81)
with (Confidence: 96)
the (Confidence: 96)
patient's (Confidence: 75)
identification (Confidence: 95)
and (Confidence: 93)
contains (Confidence: 96)
3 (Confidence: 96)
pieces (Confidence: 96)
of (Confidence: 96)
tan (Confidence: 96)
soft (Confidence: 94)
tissue (Confidence: 96)
measuring (Confidence: 96)
0.2 (Confidence: 94)
to (Confidence: 85)
0.4m (Confidence: 66)
in (Confidence: 95)
greatest (Confidence: 75)
dimension. (Confidence: 88)
+1 (Confidence: 24)
submitted (Confidence: 96)
im (Confidence: 90)
toto (Confidence: 88)
2. (Confidence: 91)
The (Confidence: 96)
specimen (Confidence: 92)
container (Confidence: 96)
is (Confidence: 93)
labelled (Confidence: 62)
with (Confidence: 96)
the (Confidence: 96)
patient's (Confidence: 89)
identification (Confidence: 92)
and (Confidence: 96)
contains (Confidence: 96)
4 (Confidence: 95)
pieces (Confidence: 95)
of (Confidence: 96)
tan (Confidence: 92)
soft (Confidence: 92)
tissue (Confidence: 95)
measuring (Confidence: 92)
0.6 (Confidence: 96)
to (Confidence: 96)
0.7 (Confidence: 96)
cm (Confidence: 96)
in (Confidence: 96)
greatest (Confidence: 66)
dimension. (Confidence: 96)
~4 (Confidence: 38)
submited (Confidence: 79)
in (Confidence: 93)
tote (Confidence: 94)
3, (Confidence: 72)
The (Confidence: 96)
specimen (Confidence: 95)
container (Confidence: 67)
is (Confidence: 95)
labelled (Confidence: 61)
with (Confidence: 96)
the (Confidence: 96)
patient's (Confidence: 88)
identification (Confidence: 71)
and (Confidence: 95)
contains (Confidence: 95)
4 (Confidence: 96)
pieces (Confidence: 92)
of (Confidence: 95)
tan (Confidence: 95)
soft (Confidence: 96)
tissue (Confidence: 95)
measuring (Confidence: 92)
0.2 (Confidence: 92)
to (Confidence: 91)
0.6 (Confidence: 94)
cm (Confidence: 94)
in (Confidence: 88)
greatesi (Confidence: 49)
dimension. (Confidence: 83)
74 (Confidence: 14)
submitted (Confidence: 83)
in (Confidence: 94)
tote (Confidence: 85)
4. (Confidence: 83)
The (Confidence: 95)
specimen (Confidence: 96)
container (Confidence: 92)
labelled (Confidence: 78)
with (Confidence: 96)
the (Confidence: 96)
patient's (Confidence: 82)
Gantification (Confidence: 70)
and (Confidence: 96)
contains (Confidence: 68)
multiple (Confidence: 84)
fragments (Confidence: 95)
of (Confidence: 93)
tan (Confidence: 93)
sot (Confidence: 71)
tissue (Confidence: 87)
measunng (Confidence: 59)
0.6 (Confidence: 0)
x (Confidence: 0)
0.6 (Confidence: 66)
x0.2 (Confidence: 83)
cm (Confidence: 92)
in (Confidence: 93)
aggregate (Confidence: 95)
dimension, (Confidence: 85)
71 (Confidence: 62)
submitted (Confidence: 87)
in (Confidence: 91)
toto (Confidence: 67)
Grossed (Confidence: 92)
by! (Confidence: 92)
N. (Confidence: 32)
Saito, (Confidence: 78)
Pathologists" (Confidence: 87)
Assistant (Confidence: 95)
Microscopic (Confidence: 89)
Description (Confidence: 95)
RESULTS (Confidence: 96)
Mismatch (Confidence: 94)
Repair (Confidence: 95)
Immnunohistoche (Confidence: 46)
mastry (Confidence: 75)
(IHC) (Confidence: 90)
Testing (Confidence: 96)
for (Confidence: 96)
Mismatch (Confidence: 93)
Repatr (Confidence: 90)
(MMR) (Confidence: 93)
Proteins (Confidence: 95)
MLH1 (Confidence: 64)
Result: (Confidence: 96)
Loss (Confidence: 90)
of (Confidence: 96)
nuclear (Confidence: 1)
expression (Confidence: 95)
MSH2 (Confidence: 91)
Result) (Confidence: 68)
Intact (Confidence: 96)
nuclear (Confidence: 94)
expression (Confidence: 94)
MSH6 (Confidence: 81)
Result: (Confidence: 63)
Intact (Confidence: 84)
nuclear (Confidence: 83)
expression (Confidence: 96)
PMS2 (Confidence: 90)
Result (Confidence: 75)
Loss (Confidence: 88)
of (Confidence: 96)
nuclear (Confidence: 93)
expression (Confidence: 95)
Background (Confidence: 93)
nonneoplastic (Confidence: 79)
tissue (Confidence: 92)
/ (Confidence: 90)
Internal (Confidence: 69)
control (Confidence: 72)
with (Confidence: 96)
intact (Confidence: 96)
nuclear (Confidence: 53)
expression (Confidence: 96)
HER?2 (Confidence: 41)
Test(s) (Confidence: 91)
Performed (Confidence: 93)
HER2 (Confidence: 91)
by (Confidence: 96)
IHC (Confidence: 55)
Results (Confidence: 73)
Negative (Confidence: 96)
(Score (Confidence: 54)
0) (Confidence: 69)
2 (Confidence: 15)
Sinai (Confidence: 0)
| (Confidence: 54)
Mount (Confidence: 93)
Sinai (Confidence: 95)
Hospital (Confidence: 96)
Pathology (Confidence: 93)
& (Confidence: 93)
Laboratory (Confidence: 96)
Medicine (Confidence: 96)
er (Confidence: 37)
Health (Confidence: 93)
| (Confidence: 84)
eset (Confidence: 0)
wet (Confidence: 42)
Lenovtc (Confidence: 25)
Hecttn (Confidence: 19)
Comptex (Confidence: 34)
BOO (Confidence: 51)
University (Confidence: 0)
Ave (Confidence: 83)
, (Confidence: 51)
Suite (Confidence: 60)
6.500, (Confidence: 66)
Totorty, (Confidence: 46)
ON, (Confidence: 72)
Curae, (Confidence: 25)
MSG (Confidence: 36)
1X5 (Confidence: 87)
0 (Confidence: 16)
416-588-4800 (Confidence: 51)
445? (Confidence: 43)
f (Confidence: 61)
416-598-6628 (Confidence: 60)
Chine (Confidence: 67)
1 (Confidence: 69)
ENDO (Confidence: 91)
Medical (Confidence: 60)
Record (Confidence: 70)
# (Confidence: 70)
8066203 (Confidence: 0)
Clinee (Confidence: 45)
Name: (Confidence: 94)
ENDOSCOPY (Confidence: 95)
Last (Confidence: 96)
Name (Confidence: 93)
TESTINGLONGNAME, (Confidence: 68)
Physician: (Confidence: 89)
BOLLEGALA, (Confidence: 85)
DR, (Confidence: 89)
NATASHA (Confidence: 71)
First, (Confidence: 90)
Middle: (Confidence: 33)
MARYLOUWCH (Confidence: 82)
Procedure (Confidence: 85)
Dale: (Confidence: 69)
2024-05-31 (Confidence: 71)
DOBAGender: (Confidence: 61)
28 (Confidence: 94)
NOY (Confidence: 81)
1981 (Confidence: 96)
Accession (Confidence: 17)
Date: (Confidence: 93)
2024-05-31 (Confidence: 86)
Health (Confidence: 96)
Card (Confidence: 90)
# (Confidence: 67)
Report (Confidence: 63)
Dete: (Confidence: 10)
 2024-07-12* (Confidence: 0)
viet (Confidence: 59)
# (Confidence: 86)
SUPPLEMENTAL (Confidence: 96)
SURGICAL (Confidence: 96)
PATHOLOGY (Confidence: 95)
REPORT (Confidence: 95)
SPS-24-15414 (Confidence: 91)
Aaron (Confidence: 96)
Pollet, (Confidence: 47)
MD,FRCPC (Confidence: 43)
Me (Confidence: 51)
SoeocOoDS (Confidence: 0)
“all (Confidence: 39)
New (Confidence: 46)
| (Confidence: 60)
TBSTINGLONGHAME. (Confidence: 29)
- (Confidence: 0)
Page (Confidence: 51)
Tas] (Confidence: 20)
